| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/16/2002 | US20020058668 3-aryl substituted pyrazolo[4,3-D]pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands |
| 05/16/2002 | US20020058667 Compounds specific to adenosine A1 receptors and uses thereof |
| 05/16/2002 | US20020058665 For use in cancer therapy |
| 05/16/2002 | US20020058663 Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders |
| 05/16/2002 | US20020058662 Phthalazine derivatives as phosphodiesterase 4 inhibitors |
| 05/16/2002 | US20020058658 For use in therapy and prophylaxis of diabetes and obesity |
| 05/16/2002 | US20020058655 New use |
| 05/16/2002 | US20020058654 For therapy of uterine fibroids, endometriosis, polycystic ovarian disease, dysfunctional uterine bleeding, breast cancer and ovarian cancer; depletion of oocytes; spermatocyte depletion; for female and male contraception |
| 05/16/2002 | US20020058653 Administering cyclic polyamine compound to elevate white blood cell (WBC) count |
| 05/16/2002 | US20020058652 Pharmaceutical compositions and methods for use |
| 05/16/2002 | US20020058651 Estra-1,3,5(10), 16-tetraene derivatives |
| 05/16/2002 | US20020058650 Penetration enhancing and irritation reducing systems |
| 05/16/2002 | US20020058649 Administering during follicular phase of female menstrual cycle and in luteal phase, a competitive progesterone antagonist, which is less than an ovulation-inhibiting dose and less than an abortion-inductive dose |
| 05/16/2002 | US20020058648 Useful in estrogen replacement therapy |
| 05/16/2002 | US20020058647 Preparing a slurry of pamidronic acid in water, combining aqueous sodium hydroxide with slurry to obtain disodium pamidronate; packaging solution in sealed containers to obtain unit dosage |
| 05/16/2002 | US20020058646 Substituted pyridine compounds useful for controlling chemical synaptic transmission |
| 05/16/2002 | US20020058644 Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B) |
| 05/16/2002 | US20020058642 Such as the NSAIDS ketoprofen and ibuprofen; synergistic |
| 05/16/2002 | US20020058638 Decreasing blood glucose levels, inhibiting PEPCK expression, decreasing blood insulin levels, decreasing insulin resistance, increasing insulin sensitivity, decreasing blood triglyceride levels or decreasing blood cholesterol levels |
| 05/16/2002 | US20020058637 Methods of inhibiting tau-protein kinase I activity, inhibiting neuronal cell death and treating alzheimer's disease and tau-protein kinase I |
| 05/16/2002 | US20020058636 Ribozymes targeting the retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs |
| 05/16/2002 | US20020058635 Purine L-nucleosides, analogs and uses thereof |
| 05/16/2002 | US20020058633 Stabilizing glycoglyceride by adding a sequestering agent; treating, protecting, caring for, removing make-up from and/or cleansing the skin, the lips and/or the hair |
| 05/16/2002 | US20020058632 Medicament and therapeutical method for treating idiopathic asthenozoospermia |
| 05/16/2002 | US20020058630 Urea heterocycliccarbonyl-substituted aspartic or glutamic acid derivatives |
| 05/16/2002 | US20020058629 S-nitrosothiols as agents for the treatment of circulatory dysfunctions |
| 05/16/2002 | US20020058628 Antioxidants and intracellular glutathione raising agents for therapeutic treatments |
| 05/16/2002 | US20020058618 Method for the treatmennt or prevention of a disease mediated by the alpha-2B-adrenoceptor |
| 05/16/2002 | US20020058616 Coadministration of a an oral bioavailability-enhancing agent (e.g., a cyclosporin F or ketoconazole) with a drug that exhibits poor or inconsistent oral bioavailability (e.g., paclitaxel, docetaxel or etoposide) |
| 05/16/2002 | US20020058606 Treatment of sexual dysfunction |
| 05/16/2002 | US20020058290 Stable genetically engineered muscle cell; for use in the generation of modulators for treatment of cancer, metabolic defects, cachexia and aging defects |
| 05/16/2002 | US20020058288 Compound for use in the detection and prevention of parasitic infection of humans |
| 05/16/2002 | US20020058267 Nucleotide sequences coding polypeptide for use in the treatment of alzheimer's disease |
| 05/16/2002 | US20020058238 Stop smoking method and composition |
| 05/16/2002 | US20020058078 Incubating acidified vegetation water from olives for at least two months, until at least 75% of oleoeuropein originally present in the vegetation water has been converted to hydroxytyrosol. |
| 05/16/2002 | US20020058077 Cancer chemotherapeutical and chemopreventive agent |
| 05/16/2002 | US20020058075 Administering synephrine, hordenine, octopamine, tyramine or N-methyltyramine. |
| 05/16/2002 | US20020058067 Solid drug delivery system |
| 05/16/2002 | US20020058066 Outer layer portion containing cilostazol, a water-insoluble substance, such as ethyl cellulose, and a hydrophilic hydrogel forming substance, such as hydroxypropyl methyl cellulose. |
| 05/16/2002 | US20020058065 Insoluble drug particle compositions with improved fasted-fed effects |
| 05/16/2002 | US20020058063 Stable pharmaceutical dosage form for paroxetin anhydrate |
| 05/16/2002 | US20020058062 At least 13% glucoside isoflavones and 0.6-1.5 parts 3 soya saponins per 1 part by weight of glucoside isoflavones; treating pre or post menopausal symptoms, breast and prostate cancer, and alcoholism |
| 05/16/2002 | US20020058061 Pharmaceutical dosage form for pulsatile delivery of methylphenidate |
| 05/16/2002 | US20020058058 Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures |
| 05/16/2002 | US20020058052 Amphipatic lipid containing a hydroxy and amide group; and of a surfactant in an aqueous medium; a washing-away type cosmetic composition comprising the dispersion |
| 05/16/2002 | US20020058050 Treating pain by administering 24 hours opioid formulations exhibiting rapid rise of drug level |
| 05/16/2002 | US20020058049 Stable ophthalmic preparation |
| 05/16/2002 | US20020058048 Contains a nonionic, amphoteric or cationic surfactant in an amount effective to eliminate or substantially ameliorate burning pain caused by capsaicin. |
| 05/16/2002 | US20020058036 Novel fibroblast growth factor and nucleic acids encoding same |
| 05/16/2002 | US20020058035 Reducing FSH levels by administering a GnRH antagonist to reduce both plasma FSH and LH levels; treating prostatic intraepithelial neoplasia, pedophilia, infertility, vaginal bleeding; in vitro fertilization and male contraception |
| 05/16/2002 | US20020058026 HMG CoA reductase inhibitor medications combined wih CoEnzyme Q-10 |
| 05/16/2002 | US20020058022 Novel compounds |
| 05/16/2002 | US20020058013 Bacterial flora-controlling agent; periodontal-pocket bacterial flora-controlling agent that will eliminate or convert the bacteria, fungi, viruses and other microbes into a group of symbiotic bacteria. |
| 05/16/2002 | US20020058011 Aerosol formulation containing particulate formoterol, propellant and polar cosolvent |
| 05/16/2002 | US20020058009 Pulmonary delivery in treating disorders of the central nervous system |
| 05/16/2002 | US20020058008 Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins |
| 05/16/2002 | US20020056827 Piezoelectric element and process for production thereof |
| 05/16/2002 | US20020056816 Surface plasmon enhanced illumination system |
| 05/16/2002 | US20020056410 Method for the production of low defect density silicon |
| 05/16/2002 | US20020056206 Spray drying process and compositions of fenofibrate |
| 05/16/2002 | DE10114222C1 Tropolonato-silicon derivatives useful for the prevention and treatment of cancers |
| 05/16/2002 | DE10056014A1 Laminated plaster with active substance, used as transdermal therapeutic system, has impermeable barrier layer on side away from skin and separable carrier layer with adhesive on side towards skin |
| 05/16/2002 | DE10054492A1 Reduktive Aminierung von alpha-Ketodicarbonsäurederivaten Reductive amination of alpha-Ketodicarbonsäurederivaten |
| 05/16/2002 | DE10054294A1 Topische Behandlung bei der Mastalgie Topical treatment of mastalgia |
| 05/16/2002 | DE10054279A1 Verwendung von Liganden von Todesrezeptoren oder RIP zur Auslösung des Caspase-unabhängigen Zelltods und Verbindungen zur Inhibition des Caspase-unabhängigen Zelltods Use of ligands of death receptors or RIP to trigger the caspase-independent cell death and compounds for inhibition of the caspase-independent cell death |
| 05/16/2002 | DE10053795A1 5-HT6 Receptor antagonist medicaments, useful for treating central nervous system disorders such as Alzheimer's disease, comprising naphthalene N-phenylsulfonamide derivatives |
| 05/16/2002 | DE10053053A1 Pharmazeutische Formulierungen zur Hemmung von entzündlichen Arthritiden Pharmaceutical formulations for inhibition of inflammatory arthritis |
| 05/16/2002 | DE10048510A1 Lagerstabile Infusionslösung des Ciprofloxacins mit verringertem Säuregehalt A storage-stable infusion of ciprofloxacin with reduced acidity |
| 05/16/2002 | CA2512476A1 Cyanopyrrolidine derivatives |
| 05/16/2002 | CA2429012A1 New pharmaceutical compositions based on tiotropium salts and salts of salmeterol |
| 05/16/2002 | CA2428808A1 Aryl phosphate derivatives of d4t |
| 05/16/2002 | CA2428784A1 Oral pharmaceutical composition containing a block copolymer |
| 05/16/2002 | CA2428669A1 High-density lipoprotein-cholesterol level elevating agent |
| 05/16/2002 | CA2428453A1 C. elegans genes involved in viability and/or reproduction and uses thereof |
| 05/16/2002 | CA2428318A1 Synergistic medicament containing aromatic agents and having an antagonistic, regenerative and/or protagonist decontamination effect |
| 05/16/2002 | CA2428266A1 Substituted alkyldiamines as inhibitors of plasmepsin or related proteases |
| 05/16/2002 | CA2428207A1 Therapeutic agents for keratoconjunctival diseases comprising farnesylacetic acid as active ingredient |
| 05/16/2002 | CA2428204A1 Lipid peroxide-lowering compositions |
| 05/16/2002 | CA2428181A1 Pharmaceutical preparation of percutaneous absorption type |
| 05/16/2002 | CA2428179A1 Compositions of n-(methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosaccharides |
| 05/16/2002 | CA2428164A1 Method for the treatment of inflammation |
| 05/16/2002 | CA2427779A1 Imidazo-triazine derivatives as ligands for gaba receptors |
| 05/16/2002 | CA2427774A1 Inhibitors of thromboxane formation and action |
| 05/16/2002 | CA2427757A1 Therapeutic uses for ip3 receptor-mediated calcium channel modulators |
| 05/16/2002 | CA2427350A1 Pyrimidine derivatives and their use as neuropeptide y receptor ligands |
| 05/16/2002 | CA2427283A1 Device and method for the cessation of smoking |
| 05/16/2002 | CA2426730A1 Calcilytic compounds |
| 05/16/2002 | CA2426716A1 Acid derivatives useful as serine protease inhibitors |
| 05/16/2002 | CA2426049A1 Improved treatment |
| 05/16/2002 | CA2426037A1 A "bach" g protein coupled receptor polypeptide and polynucleotide encoding this receptor |
| 05/16/2002 | CA2425688A1 Extended release erythromycin derivatives |
| 05/16/2002 | CA2425594A1 Compositions containing hydrolytically unstable compounds |
| 05/16/2002 | CA2425245A1 Novel compounds for treatment of cardiac arrhythmia synthesis, and methods of use |
| 05/16/2002 | CA2421594A1 3-substituted oxindole beta 3 agonists |
| 05/16/2002 | CA2421154A1 Peroxisome proliferator activated receptor alpha agonists |
| 05/16/2002 | CA2396638A1 Anticancer agent |
| 05/15/2002 | EP1205754A2 Method for screening plant extracts for active ingredients |
| 05/15/2002 | EP1205559A1 Method for detecting pathogenic microorganism and antimicrobial agent, method for evaluating the drug effect of antimicrobial agent, and antimicrobial agents |
| 05/15/2002 | EP1205489A1 Polypeptide and nucleic acids encoding the same |
| 05/15/2002 | EP1205478A1 p38MAP KINASE INHIBITORS |